Provided by Tiger Trade Technology Pte. Ltd.

Aurinia Pharmaceuticals

16.65
-0.6200-3.59%
Post-market: 16.650.00000.00%19:31 EDT
Volume:1.25M
Turnover:21.02M
Market Cap:2.22B
PE:7.23
High:17.32
Open:17.20
Low:16.63
Close:17.27
52wk High:19.25
52wk Low:10.34
Shares:133.05M
Float Shares:129.00M
Volume Ratio:0.91
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.30
EPS(LYR):2.07
ROE:66.12%
ROA:15.49%
PB:3.60
PE(LYR):8.04

Loading ...

Aurinia Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 11

Aurinia completes Kezar acquisition at $6.96 per share plus CVR

Reuters
·
May 11

Kezar Q1 net loss narrows to $5.8 million; operating loss narrows to $7.4 million

Reuters
·
May 11

Aurinia publishes corporate presentation on LUPKYNIS growth strategy in lupus nephritis

Reuters
·
May 07

Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, vs. FactSet Est of $0.20

MT Newswires Live
·
May 07

Aurinia Q1 net income rises 48% to $34.4 million; revenue climbs 24% to $77.7 million

Reuters
·
May 07

BRIEF-Aurinia Pharmaceuticals Q1 Product Revenue USD 73.563 Million

Reuters
·
May 07

Aurinia Pharmaceuticals Inc: Reiterates Its Guidance for 2026 Total Revenue of $315 Mln to $325 Mln

THOMSON REUTERS
·
May 07

Aurinia Pharmaceuticals Q1 Pretax Profit USD 43.925 Million

THOMSON REUTERS
·
May 07

Aurinia Pharmaceuticals Q1 Operating Income USD 41.422 Million

THOMSON REUTERS
·
May 07

Press Release: Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Dow Jones
·
May 07

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 30

Aurinia Pharmaceuticals announces annual shareholder meeting

Reuters
·
Apr 22

A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Its Recent Leadership Overhaul

Simply Wall St.
·
Apr 06

Aurinia Pharma to buy Kezar Life Sciences for $6.955 a share plus CVR

Reuters
·
Apr 04

Aurinia Pharmaceuticals CFO Michael Hearne files initial beneficial ownership statement

Reuters
·
Apr 03

Aurinia Pharma COO Ryan Cole files initial beneficial ownership statement

Reuters
·
Apr 03

Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Mar 31

Kezar Life Sciences takeover valuation ‘makes sense,’ says Jefferies

TIPRANKS
·
Mar 31

Aurinia to buy Kezar Life Sciences for USD 6.96 per share plus CVR

Reuters
·
Mar 30